Listed

Benitec Biopharma Inc.: Form 10-Q for the period ended Mar 31, 2022

Filed with the SEC on May 16, 2022 and accepted by EDGAR at May 16, 2022, 08:01 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-01-01 to 2022-03-31$48.0kus-gaap:Revenues
Revenue9 months2021-07-01 to 2022-03-31$73.0kus-gaap:Revenues
Research and development3 months2022-01-01 to 2022-03-31$2.2mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2021-07-01 to 2022-03-31$8.1mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-01-01 to 2022-03-31−$3.5mus-gaap:OperatingIncomeLoss
Operating income9 months2021-07-01 to 2022-03-31−$13.1mus-gaap:OperatingIncomeLoss
Net income3 months2022-01-01 to 2022-03-31−$3.3mus-gaap:NetIncomeLoss
Net income9 months2021-07-01 to 2022-03-31−$13.1mus-gaap:NetIncomeLoss
Operating cash flow9 months2021-07-01 to 2022-03-31−$11.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2021-07-01 to 2022-03-31$0us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-03-31$8.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-03-31$8.8mus-gaap:AssetsCurrent
Total assetsAt period end2022-03-31$10.1mus-gaap:Assets
Current liabilitiesAt period end2022-03-31$1.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-03-31$2.5mus-gaap:Liabilities
Shareholders' equityAt period end2022-03-31$7.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001193125-22-150924. Last ingested by Listed: Nov 14, 2026, 11:28 ET. Listed shows no prices and gives no investment advice.